New pill combo could replace chemo for some advanced breast cancers
NCT ID NCT07371910
First seen Jan 29, 2026 · Last updated May 16, 2026 · Updated 14 times
Summary
This study tests a new approach for people with a specific genetic type of advanced breast cancer (HRD-positive, HER2-negative). After initial chemotherapy, one group switches to a daily pill combination (fluorizoparib + apatinib) for long-term control, while the other group stays on standard chemo. The goal is to see if the pill combo keeps the cancer from growing longer than chemo. About 200 women aged 18-70 are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, 510030, China
Conditions
Explore the condition pages connected to this study.